Low antileishmanial drug exposure in HIV-positive visceral leishmaniasis patients on antiretrovirals: an Ethiopian cohort study.
Journal
The Journal of antimicrobial chemotherapy
ISSN: 1460-2091
Titre abrégé: J Antimicrob Chemother
Pays: England
ID NLM: 7513617
Informations de publication
Date de publication:
13 04 2021
13 04 2021
Historique:
received:
28
08
2020
accepted:
05
01
2021
pubmed:
8
3
2021
medline:
9
7
2021
entrez:
7
3
2021
Statut:
ppublish
Résumé
Despite high HIV co-infection prevalence in Ethiopian visceral leishmaniasis (VL) patients, the adequacy of antileishmanial drug exposure in this population and effect of HIV-VL co-morbidity on pharmacokinetics of antileishmanial and antiretroviral (ARV) drugs is still unknown. HIV-VL co-infected patients received the recommended liposomal amphotericin B (LAmB) monotherapy (total dose 40 mg/kg over 24 days) or combination therapy of LAmB (total dose 30 mg/kg over 11 days) plus 28 days 100 mg/day miltefosine, with possibility to extend treatment for another cycle. Miltefosine, total amphotericin B and ARV concentrations were determined in dried blood spots or plasma using LC-MS/MS. Median (IQR) amphotericin B Cmax on Day 1 was 24.6 μg/mL (17.0-34.9 μg/mL), which increased to 40.9 (25.4-53.1) and 33.2 (29.0-46.6) μg/mL on the last day of combination and monotherapy, respectively. Day 28 miltefosine concentration was 18.7 (15.4-22.5) μg/mL. Miltefosine exposure correlated with amphotericin B accumulation. ARV concentrations were generally stable during antileishmanial treatment, although efavirenz Cmin was below the 1 μg/mL therapeutic target for many patients. This study demonstrates that antileishmanial drug exposure was low in this cohort of HIV co-infected VL patients. Amphotericin B Cmax was 2-fold lower than previously observed in non-VL patients. Miltefosine exposure in HIV-VL co-infected patients was 35% lower compared with adult VL patients in Eastern Africa, only partially explained by a 19% lower dose, possibly warranting a dose adjustment. Adequate drug exposure in these HIV-VL co-infected patients is especially important given the high proportion of relapses.
Sections du résumé
BACKGROUND
Despite high HIV co-infection prevalence in Ethiopian visceral leishmaniasis (VL) patients, the adequacy of antileishmanial drug exposure in this population and effect of HIV-VL co-morbidity on pharmacokinetics of antileishmanial and antiretroviral (ARV) drugs is still unknown.
METHODS
HIV-VL co-infected patients received the recommended liposomal amphotericin B (LAmB) monotherapy (total dose 40 mg/kg over 24 days) or combination therapy of LAmB (total dose 30 mg/kg over 11 days) plus 28 days 100 mg/day miltefosine, with possibility to extend treatment for another cycle. Miltefosine, total amphotericin B and ARV concentrations were determined in dried blood spots or plasma using LC-MS/MS.
RESULTS
Median (IQR) amphotericin B Cmax on Day 1 was 24.6 μg/mL (17.0-34.9 μg/mL), which increased to 40.9 (25.4-53.1) and 33.2 (29.0-46.6) μg/mL on the last day of combination and monotherapy, respectively. Day 28 miltefosine concentration was 18.7 (15.4-22.5) μg/mL. Miltefosine exposure correlated with amphotericin B accumulation. ARV concentrations were generally stable during antileishmanial treatment, although efavirenz Cmin was below the 1 μg/mL therapeutic target for many patients.
CONCLUSIONS
This study demonstrates that antileishmanial drug exposure was low in this cohort of HIV co-infected VL patients. Amphotericin B Cmax was 2-fold lower than previously observed in non-VL patients. Miltefosine exposure in HIV-VL co-infected patients was 35% lower compared with adult VL patients in Eastern Africa, only partially explained by a 19% lower dose, possibly warranting a dose adjustment. Adequate drug exposure in these HIV-VL co-infected patients is especially important given the high proportion of relapses.
Identifiants
pubmed: 33677546
pii: 6157024
doi: 10.1093/jac/dkab013
pmc: PMC8050768
doi:
Substances chimiques
Antiprotozoal Agents
0
Pharmaceutical Preparations
0
Phosphorylcholine
107-73-3
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1258-1268Informations de copyright
© The Author(s) 2021. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy.
Références
PLoS One. 2013 Jul 05;8(7):e67946
pubmed: 23861838
Front Immunol. 2018 Jan 12;8:1943
pubmed: 29375567
AAPS J. 2014 Sep;16(5):962-74
pubmed: 25056904
Prog Lipid Res. 2001 May;40(3):149-66
pubmed: 11275265
Eur J Med Res. 2004 Feb 27;9(2):51-4
pubmed: 15090289
Drugs. 2014 Jun;74(8):839-54
pubmed: 24846578
Clin Microbiol Rev. 2008 Apr;21(2):334-59, table of contents
pubmed: 18400800
Antimicrob Agents Chemother. 2008 Aug;52(8):2855-60
pubmed: 18519729
Antimicrob Agents Chemother. 2002 Mar;46(3):828-33
pubmed: 11850268
J Antimicrob Chemother. 2012 May;67(5):1211-6
pubmed: 22302563
AIDS. 2001 Jan 5;15(1):71-5
pubmed: 11192870
Antimicrob Agents Chemother. 2012 Jul;56(7):3864-72
pubmed: 22585212
Eur J Pharmacol. 2008 Jan 28;579(1-3):104-9
pubmed: 18037401
Drug Metab Pharmacokinet. 2015 Dec;30(6):400-9
pubmed: 26645511
PLoS Negl Trop Dis. 2016 Sep 14;10(9):e0004880
pubmed: 27627654
EBioMedicine. 2020 May;55:102748
pubmed: 32361248
Pediatr Infect Dis J. 2012 May;31(5):451-4
pubmed: 22209914
J Clin Invest. 1999 Jul;104(2):147-53
pubmed: 10411543
Trans R Soc Trop Med Hyg. 2007 Jul;101(7):660-7
pubmed: 17442352
J Biol Chem. 2016 Apr 29;291(18):9638-47
pubmed: 26903515
Clin Pharmacokinet. 2007;46(2):109-32
pubmed: 17253884
Clin Pharmacokinet. 2017 Jun;56(6):583-606
pubmed: 27744580
J Antimicrob Chemother. 2012 Nov;67(11):2576-97
pubmed: 22833634
Antimicrob Agents Chemother. 2001 Dec;45(12):3487-96
pubmed: 11709329
J Antimicrob Chemother. 2017 Nov 1;72(11):3131-3140
pubmed: 28961737
Clin Pharmacokinet. 2015 Jan;54(1):23-34
pubmed: 25331712
J Chromatogr B Analyt Technol Biomed Life Sci. 2008 May 15;867(2):205-12
pubmed: 18456582
PLoS Negl Trop Dis. 2019 Jan 17;13(1):e0006988
pubmed: 30653490
J Infect Dis. 2014 Jul 1;210(1):146-53
pubmed: 24443541
Drugs. 2011 Dec 3;71(17):2277-94
pubmed: 22085385
Antimicrob Agents Chemother. 2012 Jan;56(1):536-43
pubmed: 22083471
Antimicrob Agents Chemother. 2016 Mar 25;60(4):2081-9
pubmed: 26787691
Antimicrob Agents Chemother. 2019 Jun 24;63(7):
pubmed: 31036692
PLoS Negl Trop Dis. 2014 Jun 26;8(6):e2869
pubmed: 24968313
Antimicrob Agents Chemother. 2002 Mar;46(3):834-40
pubmed: 11850269
Trans R Soc Trop Med Hyg. 2001 Nov-Dec;95(6):668-72
pubmed: 11816442
J Antimicrob Chemother. 1991 Oct;28 Suppl B:39-48
pubmed: 1778891
Antimicrob Agents Chemother. 2006 Mar;50(3):935-42
pubmed: 16495254
Clin Microbiol Infect. 2012 Mar;18(3):E37-45
pubmed: 22264314
Am J Trop Med Hyg. 2008 Oct;79(4):591-8
pubmed: 18840750
AIDS Res Hum Retroviruses. 2003 Sep;19(9):825-35
pubmed: 14585213
Antimicrob Agents Chemother. 2009 Sep;53(9):3664-74
pubmed: 19546359
Mol Pharm. 2007 Mar-Apr;4(2):281-8
pubmed: 17397240